Accordingly, inhibition of tumor glycolysis ameliorates the ability of CTLA-4 blockade to induce loss of Treg stability associated with the development of anti-tumor immunity (Zappasodi et al., 2021). The gene discussed is CTLA4; the disease is neoplasm.